<DOC>
	<DOC>NCT00109330</DOC>
	<brief_summary>This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).</brief_summary>
	<brief_title>A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine</brief_title>
	<detailed_description>A combined Tdap (Tetanus, Diphteria, Acellular Pertussis) Vaccine Used as a Booster compared to Licensed Td (Tetanus and Diphteria) vaccine</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adolescents with history of completed routine vaccination against diphtheria, tetanus, and pertussis (DTP). Use of any other investigational drug or vaccine 30 days preceding study vaccination. Chronic administration of immunosuppressants. Administration of preschool DTP vaccine within previous 5 years. Administration of Td booster within previous 10 years.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prevention of Diphtheria, Tetanus, Pertussis</keyword>
</DOC>